Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings
BenzingaApr 10 08:12 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday's session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ:AGEN) declined 17% to $0.4181 on Monday.
BenzingaApr 8 13:10 ET
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEX
BenzingaApr 8 05:15 ET
Galmed Pharmaceuticals Ltd. (GLMD) Surges After Hours: An Unexpected Rally
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) concluded its Friday's trading session with a modest 2.8% gain, leaving investors to be cautiously optimistic. However, the post-closing activity took an unforeseen turn, with GLMD experiencing a remarkable 15% surge in after-hours trading. During the typically quieter after-hours session, GLMD's stock surged, capturing investors' attention. Trading volume spiked to ...
Stocks TelegraphApr 8 03:35 ET
Galmed Pharmaceuticals Granted Nasdaq Extension
TipRanksMar 19 17:28 ET
On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance
On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance
BenzingaMar 19 17:01 ET
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
Seeking AlphaMar 18 17:45 ET
The NASH pharmaceutical market is expected to exceed $48 billion by 2035, and companies such as Novo Nordisk (NVO.US) and Lily.US (LLY.US) will begin to deploy
According to international consulting firm Research Nester, the global non-alcoholic steatohepatitis (NASH) treatment market is expected to reach US$48.3 billion by 2035.
Zhitong FinanceMar 17 21:00 ET
NASH Drug Market Expected to Surpass $48B by 2035
Seeking AlphaMar 16 12:57 ET
Express News | Galmed Announces Grant Of New Patent For Combination Of Aramchol With Resmetirom (MGL-3196, REZDIFFRA) For Treatment Of NASH And Liver Fibrosis
Moomoo 24/7Mar 15 09:02 ET
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%
MT NewswiresNov 21, 2023 15:45 ET
Sector Update: Health Care
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%.
MT NewswiresNov 21, 2023 15:32 ET
Galmed Announces a Delay in the Initiation of Its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
PR NewswireNov 20, 2023 16:32 ET
Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associated With NAFLD And NASH)"
Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associate
BenzingaOct 2, 2023 10:24 ET
Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese
BenzingaSep 26, 2023 08:43 ET
Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received
BenzingaSep 22, 2023 16:07 ET
Drugmakers Still Chasing Potentially Lucrative NASH Market, Despite Setbacks
Seeking AlphaAug 14, 2023 13:19 ET
Stocks That Hit 52-Week Lows On Thursday
 During Thursday's session, 92 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Pfizer (NYSE:PFE) was the biggest company on a market cap basis to set a new 52-week low.Bit
BenzingaAug 3, 2023 14:45 ET
No Data
No Data